The Adapt Oculus trial is unique in that it includes a patient population often overlooked in clinical trials, patients ...

The Anduril founder and Oculus creator brings his retro gaming dream to life as ModRetro eyes unicorn status with its Game Boy-inspired console.

Palmer Luckey, billionaire founder of Anduril Industries and former Oculus creator, is pitching a $1 billion plan to revive 1990s gaming consoles, Financial Times reports ...

A 69-metre long rounded LED structure featuring content that responds dynamically to passenger flow has been installed at ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced ...

In just a few short years, the rapid proliferation of AI has turned what was once the stuff of dystopian sci-fi into a reality. LeBlanc argues humanoid soldiers are a natural extension of existing ...

First registrational study to specifically evaluate a targeted treatment for patients living with ocular MG Results support planned Supplemental Biologics ...

Efgartigimod led to statistically significant improvement in key symptoms of ocular myasthenia gravis compared with placebo in a phase 3 trial.

Delivered $1.1 billion in operating income in 2025, marking first year of operating profitability VYVGART MG label expansion supported by positive ADAPT SERON and OCULUS results; PDUFA target action ...

Results from ADAPT OCULUS are expected to support a sBLA submission to the FDA to secure a label expansion for oMG.

Argenx SE ARGX on Thursday announced positive topline results from the Phase 3 ADAPT OCULUS study evaluating VYVGART in adults with ocular myasthenia gravis (oMG). It is an autoimmune disorder where ...

It's now the "final phase" of a redevelopment program.